Segmentation Quick Reference
| Dimension | Sub-Segments | Dominant Segment | Fastest Growing Segment |
| By Product | Reagents and Kits; Instruments; Software and Services | Reagents and Kits (51% share, 2025) | Instruments (10.6% CAGR) |
| By Technology | NAT; Immunoassay; Rapid Tests; Next-Generation Sequencing | Nucleic Acid Amplification Testing (45% share, 2025) | Next-Generation Sequencing (11.9% CAGR) |
| By Screening Target | Infectious Disease Panels; Blood Group Typing; Other Screening Targets | Infectious Disease Panels (53% share, 2025) | Other Screening Targets (9.4% CAGR) |
| By End-User | Blood Banks; Hospitals; Clinical Laboratories | Blood Banks (63% share, 2025) | Clinical Laboratories (11.0% CAGR) |
| By Region | North America; Europe; Asia-Pacific; South America; Middle East & Africa | North America (38% share, 2025) | Asia-Pacific (10.7% CAGR) |
Market Segmentation Overview
By Product
| Sub-Segment | Key Trend |
| Reagents and Kits | Closed-system reagent-rental contracts driving recurring revenue and vendor lock-in |
| Instruments | Synchronized global replacement cycle as 2012–2016 NAT platforms reach end-of-life |
| Software and Services | LIMS integration, AI-based result interpretation, and hemovigilance analytics |
Reagents and kits continue to dominate product-level revenue as the consumable-intensive screening model ensures high recurring purchase volumes tied to each donation unit processed. The instruments segment is entering an accelerated growth phase as large blood centers worldwide upgrade to fully automated, connectivity-enabled platforms capable of walk-away operation.
By Technology
| Sub-Segment | Key Trend |
| Nucleic Acid Amplification Testing (NAT) | Expanding panel breadth with Babesia, HEV, and dengue analytes added to multiplex cartridges |
| Immunoassay | Retained for blood-group serology, confirmatory antibody testing, and cost-effective high-volume screening |
| Rapid Tests | Primary screening modality in ~40 WHO member states lacking centralized molecular infrastructure |
| Next-Generation Sequencing | Transitioning from research-use-only to clinical deployment for metagenomic pathogen surveillance |
NAT remains the technology backbone for donor screening globally, mandated by regulatory agencies in over 80 countries. Next-generation sequencing represents the highest-growth frontier as its pathogen-agnostic detection capability addresses emerging and engineered pathogen risks that conventional targeted assays cannot cover.
By Screening Target
| Sub-Segment | Key Trend |
| Infectious Disease Panels | Panel scope expanding beyond core HIV/HBV/HCV to include Babesia, HEV, and emerging arboviruses |
| Blood Group Typing | Molecular genotyping supplementing traditional serological typing for complex cases |
| Other Screening Targets | Growing demand for sickle-cell trait, CMV, and malaria parasite detection in specific donor populations |
Infectious disease panels drive the majority of screening spend, reflecting universal regulatory mandates for HIV, HBV, and HCV testing. The category continues to expand as national regulators add new analytes to mandatory screening panels based on evolving epidemiological evidence.
By End-User
| Sub-Segment | Key Trend |
| Blood Banks | Long-term reagent-rental contracts and centralized tender procurement processes |
| Hospitals | In-house transfusion services adopting compact screening platforms for emergency and surgical use |
| Clinical Laboratories | Fastest-growing segment as reference labs expand transfusion-medicine and confirmatory testing portfolios |
Blood banks remain the dominant end-user, processing the vast majority of donations through centralized, high-volume screening workflows. Clinical laboratories are gaining share as hospital systems increasingly outsource confirmatory and supplemental testing to specialized reference facilities equipped with broader assay menus.
